[177Lu]DOTA-2P(FAPI)2 transforms the TME, increases sensitivity to PD-1/PD-L1 immunotherapy
Jan. 20, 2025
[68Ga]/[177Lu]DOTA-2P(FAPI)2 is a novel dimeric FAP-targeting radiopharmaceutical that has demonstrated increased tumor uptake and prolonged retention in different types of cancer models.